sglt2 glp-1 news Renal outcomes of inhibitors and GLP1 agonists in clinical practice SGLT2 Inhibitors vs. GLP-1 Agonists

4.1 Future clinical and research applications 4.1.1 Future research directions While reassuring data are accumulating about the safety profile of GLP-1 receptor agonists (GLP-1 RAs) used for diabetes and obesity management, there are still significant gaps in our understanding that justifies the need for well-designed multidisciplinary translational and clinical studies

The timeline varies among individuals and depends on factors such as the dosage and your metabolism

The exact combination depends on your medical profile and your providers clinical judgment, ensuring the treatment plan is tailored to your specific goals and health history

Endocrinology (1995) 136(8):358596